Skip to main content
SpringerLink
Log in

Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex

  • Review
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background

Differentiating Acinetobacter baumannii complex (ABC) infection from colonization remains difficult and further complicated in polymicrobial infections.

Purpose

To assess the frequency of polymicrobial ABC infections and associated mortality. We hypothesized a lower mortality in polymicrobial infections if ABC isolation reflects colonization in some polymicrobial infections.

Methods

A systematic review was conducted in PubMed, Scopus and CENTRAL for studies reporting ABC pulmonary and bloodstream infections. The proportion of infections that were polymicrobial and the magnitude of the association between polymicrobial (vs monomicrobial) infection and mortality were estimated with meta-analyses.

Results

Based on 80 studies (9759 infections) from 23 countries, the pooled proportion of polymicrobial infection was 27% (95% CI 22–31%) and was similarly high for bloodstream and pulmonary infections. Polymicrobial infection was variably and insufficiently defined in most (95%) studies. Considerable heterogeneity (I2 = 95%) was observed that persisted in subgroup analyses and meta-regressions. Based on 17 studies (2675 infections), polymicrobial infection was associated with lower 28-day mortality (OR = 0.75, 95% CI 0.58–0.98, I2 = 36%). However, polymicrobial infection was not associated with in-hospital mortality (OR = 0.97, 95% CI 0.69–1.35, I2 = 0%) based on 14 studies (953 infections). The quality of evidence (GRADE) for the association of polymicrobial (vs monomicrobial) infection with mortality was low and at high risk of bias.

Conclusion

Polymicrobial ABC infections are common and may be associated with lower 28-day mortality. Considering the heterogeneity of polymicrobial infections and limitations of the available literature, more research is required to clarify the clinical impact of polymicrobial (vs monomicrobial) ABC infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10:R48.

    PubMed  PubMed Central  Google Scholar 

  2. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care. 2007;11:134.

    PubMed  PubMed Central  Google Scholar 

  3. Karakonstantis S, Gikas A, Astrinaki E, Kritsotakis EI. Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients. J Hosp Infect. 2020;106:447–53.

    CAS  PubMed  Google Scholar 

  4. Mohd Sazlly Lim S, Zainal Abidin A, Liew SM, Roberts JA, Sime FB. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis. J Infect. 2019;79:593–600.

    CAS  PubMed  Google Scholar 

  5. Livermore DM, Hill RL, Thomson H, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents. 2010;35:19–24.

    CAS  PubMed  Google Scholar 

  6. Martín-Aspas A, Guerrero-Sánchez FM, García-Colchero F, Rodríguez-Roca S, Girón-González J-A. Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infect Drug Resistance. 2018;11:861–72.

    Google Scholar 

  7. Ye JJ, Lin HS, Kuo AJ, et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect. 2011;63:351–61.

    PubMed  Google Scholar 

  8. Wang YC, Ku WW, Yang YS, et al. Is polymicrobial bacteremia an independent risk factor for mortality in Acinetobacter baumannii bacteremia? J Clin Med. 2020;9:153.

    CAS  PubMed Central  Google Scholar 

  9. Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. J Chemother. 2020;33:1–11.

    PubMed  Google Scholar 

  10. Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp; systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020;56:106065.

    CAS  PubMed  Google Scholar 

  11. Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019;75:271–82.

    Google Scholar 

  12. Karakonstantis S, Kritsotakis EI, Gikas A. Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece. J Chemother. 2020. https://doi.org/10.1080/1120009X.2020.1839689.

    Article  PubMed  Google Scholar 

  13. Karakonstantis S, Kritsotakis E, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline an approach based on the mechanisms of resistance to carbapenems. Infection. 2020;48:835–51.

    CAS  PubMed  Google Scholar 

  14. Russo A, Giuliano S, Ceccarelli G, et al. Comparison of septic shock due to multidrug-resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae in intensive care unit patients. Antimicrob Agents Chemother. 2018;62:e02562–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Robenshtok E, Paul M, Leibovici L, et al. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect. 2006;64:282–7.

    CAS  PubMed  Google Scholar 

  16. Leão AC, Menezes PR, Oliveira MS, Levin AS. Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. BMC Infect Dis. 2016;16:386.

    PubMed  PubMed Central  Google Scholar 

  17. Zheng JY, Huang SS, Huang SH, Ye JJ. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect. 2020;53:854–65.

    CAS  PubMed  Google Scholar 

  18. Balkhair A, Al-Muharrmi Z, Al’Adawi B, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend. Int J Infect Dis. 2019;85:10–5.

    CAS  PubMed  Google Scholar 

  19. Lee MJ, Jang SJ, Li XM, et al. Comparison of rpoB gene sequencing, 16S rRNA gene sequencing, gyrB multiplex PCR, and the VITEK2 system for identification of Acinetobacter clinical isolates. Diagn Microbiol Infect Dis. 2014;78:29–34.

    CAS  PubMed  Google Scholar 

  20. Lee SY, Shin JH, Kim SH, Shin MG, Suh SP, Ryang DW. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based VITEK MS system for the identification of Acinetobacter species from blood cultures: comparison with VITEK 2 and MicroScan systems. Ann Lab Med. 2015;35:62–8.

    CAS  PubMed  Google Scholar 

  21. Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci OA. 2019;5:FSO395.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Guyatt G, Busse J. Methods comment: risk of bias in cohort studies. https://www.evidencepartners.com/resources/methodological-resources/risk-of-bias-in-cohort-studies/ Accessed 13 July 2021.

  23. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.

    PubMed  Google Scholar 

  24. Foroutan F, Guyatt G, Zuk V, et al. GRADE Guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62–70.

    PubMed  Google Scholar 

  25. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60.

    PubMed  Google Scholar 

  26. Viechtbauer W. Conducting meta-analyses in R with the metafor. Package. 2010;2010(36):48.

    Google Scholar 

  27. Harrer M, Cuijpers P, Furukawa T, Ebert DD. dmetar: Companion R package for the guide 'doing meta-analysis in R'. R package version 0.0.9000. http://dmetar.protectlab.org/ Accessed 13 July 2021.

  28. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synthesis Methods. 2019;10:476–83.

    Google Scholar 

  29. Lin L, Chu H. Meta-analysis of proportions using generalized linear mixed models. Epidemiology. 2020;31:713–7.

    PubMed  PubMed Central  Google Scholar 

  30. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). www.training.cochrane.org/handbook Accessed 13 July 2021.

  31. Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21:2641–52.

    PubMed  Google Scholar 

  32. Olkin I, Dahabreh IJ, Trikalinos TA. GOSH—a graphical display of study heterogeneity. Res Synth Methods. 2012;3:214–23.

    PubMed  Google Scholar 

  33. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.

    PubMed  Google Scholar 

  34. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.

    CAS  PubMed  Google Scholar 

  35. Hsieh Y-C, Wang S-H, Chen Y-Y, et al. Association of capsular types with carbapenem resistance, disease severity, and mortality in Acinetobacter baumannii. Emerg Microb Infect. 2020;9:2094–104.

    CAS  Google Scholar 

  36. Russo A, Bassetti M, Bellelli V, et al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective. Observ Study Infect Dis Ther. 2020;10:187–200.

    Google Scholar 

  37. Son H-J, Cho EB, Bae M, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Open Forum Infect Dis. 2020;7(10):ofaa378. https://doi.org/10.1093/ofid/ofaa378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Choi SH, Cho EB, Chung JW, Lee MK. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center. J Infect Chemother. 2019;25:6–11.

    PubMed  Google Scholar 

  39. Chuang YC, Cheng A, Sun HY, et al. Microbiological and clinical characteristics of Acinetobacter baumannii bacteremia: implications of sequence type for prognosis. J Infect. 2019;78:106–12.

    PubMed  Google Scholar 

  40. Yoon EJ, Kim D, Lee H, et al. Counter clinical prognoses of patients with bloodstream infections between causative Acinetobacter baumannii clones ST191 and ST451 belonging to the international clonal lineage II. Front Public Health. 2019;7:233.

    PubMed  PubMed Central  Google Scholar 

  41. Ju MH, Yao YL, Du CL, Chen S, Song YL. Subsequent multidrug-resistant bacteremia is a risk factor for short-term mortality of patients with ventilator-associated pneumonia caused by Acinetobacter baumannii in intensive care unit: a multicenter experience. Chin Med J (Engl). 2018;131:361–3.

    Google Scholar 

  42. Kim T, Lee EJ, Park SY, et al. Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: a retrospective multicenter study in Korea. Medicine (Baltimore). 2018;97: e12984.

    Google Scholar 

  43. Pailhoriès H, Tiry C, Eveillard M, Kempf M. Acinetobacter pittii isolated more frequently than Acinetobacter baumannii in blood cultures: the experience of a French hospital. J Hosp Infect. 2018;99:360–3.

    PubMed  Google Scholar 

  44. Cheng A, Chuang YC, Sun HY, et al. Should we treat patients with only one set of positive blood cultures for extensively drug-resistant Acinetobacter baumannii the same as multiple sets? PLoS ONE. 2017;12: e0180967.

    PubMed  PubMed Central  Google Scholar 

  45. Jang JY, Kwon HY, Choi EH, Lee WY, Shim H, Bae KS. Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii. J Crit Care. 2017;40:251–6.

    CAS  PubMed  Google Scholar 

  46. Kim J, Lee J-Y, Lee H, et al. Microbiological features and clinical impact of the type VI secretion system (T6SS) in Acinetobacter baumannii isolates causing bacteremia. Virulence. 2017;8:1378–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Lee YT, Wang YC, Kuo SC, et al. Multicenter study of clinical features of breakthrough Acinetobacter bacteremia during carbapenem therapy. Antimicrob Agents Chemother. 2017;61: e0093117.

    Google Scholar 

  48. Marchaim D, Levit D, Zigron R, et al. Clinical and molecular epidemiology of Acinetobacter baumannii bloodstream infections in an endemic setting. Future Microbiol. 2017;12:271–83.

    CAS  PubMed  Google Scholar 

  49. Patamatamkul S, Klungboonkrong V, Praisarnti P, Jirakiat K. A case-control study of community-acquired Acinetobacter baumannii pneumonia and melioidosis pneumonia in northeast Thailand: an emerging fatal disease with unique clinical features. Diagn Microbiol Infect Dis. 2017;87:79–86.

    PubMed  Google Scholar 

  50. Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents. 2016;48:492–7.

    CAS  PubMed  Google Scholar 

  51. Freire MP, de Oliveira GD, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:352–8.

    CAS  PubMed  Google Scholar 

  52. Gu Z, Han Y, Meng T, et al. Risk factors and clinical outcomes for patients with Acinetobacter baumannii bacteremia. Medicine (Baltimore). 2016;95: e2943.

    Google Scholar 

  53. Liu Q, Li W, Du X, et al. Risk and prognostic factors for multidrug-resistant Acinetobacter baumannii complex bacteremia: a retrospective study in a tertiary hospital of West China. PLoS ONE. 2015;10: e0130701.

    PubMed  PubMed Central  Google Scholar 

  54. Özvatan T, Akalın H, Sınırtaş M, et al. Nosocomial Acinetobacter pneumonia: treatment and prognostic factors in 356 cases. Respirology. 2016;21:363–9.

    PubMed  Google Scholar 

  55. Royer S, Faria AL, Seki LM, et al. Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with ventilator-associated pneumonia in an adult intensive care unit at a university hospital. Braz J Infect Dis. 2015;19:350–7.

    PubMed  Google Scholar 

  56. Wang YC, Lee YT, Yang YS, et al. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure. Clin Microbiol Infect. 2015;21:758–64.

    PubMed  Google Scholar 

  57. He L, Meng J, Huang D, Hu C, Pan P. Multidrug-resistant Acinetobacter baumannii infection in intensive care unit: a retrospective analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015;40:1327–32.

    CAS  PubMed  Google Scholar 

  58. Choi HK, Kim YK, Kim HY, Uh Y. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J. 2014;55:118–25.

    CAS  PubMed  Google Scholar 

  59. Nutman A, Glick R, Temkin E, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20:O1028–34.

    CAS  PubMed  Google Scholar 

  60. Porter KA, Rhodes J, Dejsirilert S, et al. Acinetobacter bacteraemia in Thailand: evidence for infections outside the hospital setting. Epidemiol Infect. 2014;142:1317–27.

    CAS  PubMed  Google Scholar 

  61. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis. 2014;14:572.

    PubMed  PubMed Central  Google Scholar 

  62. Vandepitte WP, Berge J, Andersson R. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia. J Med Assoc Thai. 2014;97(Suppl 11):S129–39.

    PubMed  Google Scholar 

  63. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141:1214–22.

    CAS  PubMed  Google Scholar 

  64. De AS, Rathi MR, Mathur MM. Mortality audit of neonatal sepsis secondary to Acinetobacter. J Glob Infect Dis. 2013;5:3–7.

    PubMed  PubMed Central  Google Scholar 

  65. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE. 2012;7: e52349.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Tigen ET, Koltka EN, Dogru A, Orhon ZN, Gura M, Vahaboglu H. Impact of the initiation time of colistin treatment for Acinetobacter infections. J Infect Chemother. 2013;19:703–8.

    CAS  PubMed  Google Scholar 

  67. Mathai AS, Oberoi A, Madhavan S, Kaur P. Acinetobacter infections in a tertiary level intensive care unit in northern India: epidemiology, clinical profiles and outcomes. J Infect Public Health. 2012;5:145–52.

    PubMed  Google Scholar 

  68. Chang HC, Chen YC, Lin MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. J Formos Med Assoc. 2011;110:564–71.

    PubMed  Google Scholar 

  69. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother. 2011;55:4844–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Lee YC, Huang YT, Tan CK, et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother. 2011;66:1839–46.

    CAS  PubMed  Google Scholar 

  71. Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci. 2011;26:325–31.

    PubMed  PubMed Central  Google Scholar 

  72. Nomanpour B, Ghodousi A, Babaei A, Abtahi H, Tabrizi M, Feizabadi M. Rapid, cost-effective, sensitive and quantitative detection of Acinetobacter baumannii from pneumonia patients. Iran J Microbiol. 2011;3:162–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol. 2011;60:605–11.

    PubMed  Google Scholar 

  74. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25:343–8.

    PubMed  Google Scholar 

  75. Edis EC, Hatipoglu ON, Tansel O, Sut N. Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agents. Ann Thorac Med. 2010;5:92–6.

    PubMed  PubMed Central  Google Scholar 

  76. Kang G, Hartzell JD, Howard R, et al. Mortality associated with Acinetobacter baumannii complex bacteremia among patients with war-related trauma. Infect Control Hosp Epidemiol. 2010;31:92–4.

    PubMed  Google Scholar 

  77. Munoz-Price LS, Zembower T, Penugonda S, et al. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol. 2010;31:1057–62.

    PubMed  Google Scholar 

  78. Aguirre-Avalos G, Mijangos-Méndez JC, Zavala-Silva ML, Coronado-Magaña H, Amaya-Tapia G. Bacteremia caused by Acinetobacter baumannii among patients in critical care. Gac Med Mex. 2009;145:21–5.

    PubMed  Google Scholar 

  79. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol. 2007;28:293–8.

    PubMed  Google Scholar 

  80. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007;13:196–8.

    CAS  PubMed  Google Scholar 

  81. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007;59:525–30.

    CAS  PubMed  Google Scholar 

  82. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–9.

    PubMed  Google Scholar 

  83. Malacarne P, Corini M, Maremmani P, Viaggi B, Verdigi S. Diagnostic characteristics of routine surveillance cultures of endotracheal aspirate samples in cases of late-onset ventilator-associated pneumonia due to Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2007;28:867–9.

    PubMed  Google Scholar 

  84. Medina J, Formento C, Pontet J, et al. Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species. J Crit Care. 2007;22:18–26.

    PubMed  Google Scholar 

  85. Segal SC, Zaoutis TE, Kagen J, Shah SS. Epidemiology of and risk factors for Acinetobacter species bloodstream infection in children. Pediatr Infect Dis J. 2007;26:920–6.

    PubMed  Google Scholar 

  86. Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman CI. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J Burn Care Res. 2007;28:248–54.

    PubMed  Google Scholar 

  87. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31:649–55.

    PubMed  Google Scholar 

  88. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med. 2003;29:471–5.

    PubMed  Google Scholar 

  89. Rodríguez-Baño J, Pascual A, Gálvez J, et al. Acinetobacter baumannii bacteremia: clinical and prognostic features. Enferm Infecc Microbiol Clin. 2003;21:242–7.

    PubMed  Google Scholar 

  90. Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect. 2003;54:32–8.

    CAS  PubMed  Google Scholar 

  91. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis. 2001;33:939–46.

    PubMed  Google Scholar 

  92. Valero C, García Palomo JD, Matorras P, Fernández-Mazarrasa C, González Fernández C, Fariñas MC. Acinetobacter bacteraemia in a teaching hospital, 1989–1998. Eur J Intern Med. 2001;12:425–9.

    CAS  PubMed  Google Scholar 

  93. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000;31:690–7.

    CAS  PubMed  Google Scholar 

  94. Siau H, Yuen KY, Ho PL, Wong SS, Woo PC. Acinetobacter bacteremia in Hong Kong: prospective study and review. Clin Infect Dis. 1999;28:26–30.

    CAS  PubMed  Google Scholar 

  95. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis. 1999;28:59–66.

    CAS  PubMed  Google Scholar 

  96. Poutanen SM, Louie M, Simor AE. Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults. Eur J Clin Microbiol Infect Dis. 1997;16:737–40.

    CAS  PubMed  Google Scholar 

  97. Cisneros JM, Reyes MJ, Pachón J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996;22:1026–32.

    CAS  PubMed  Google Scholar 

  98. Siau H, Yuen KY, Wong SS, Ho PL, Luk WK. The epidemiology of Acinetobacter infections in Hong Kong. J Med Microbiol. 1996;44:340–7.

    CAS  PubMed  Google Scholar 

  99. Kurosu I. Bacteremia with Acinetobacter species–clinicopathological characteristics of 27 cases. Kansenshogaku Zasshi. 1995;69:895–902.

    CAS  PubMed  Google Scholar 

  100. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore). 1995;74:340–9.

    CAS  Google Scholar 

  101. Tilley PA, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis. 1994;18:896–900.

    CAS  PubMed  Google Scholar 

  102. Fuchs GJ 3rd, Jaffe N, Pickering LK. Acinetobacter calcoaceticus sepsis in children with malignancies. Pediatr Infect Dis. 1986;5:545–9.

    PubMed  Google Scholar 

  103. Smego RA Jr. Endemic nosocomial Acinetobacter calcoaceticus bacteremia. Clinical significance, treatment, and prognosis. Arch Intern Med. 1985;145:2174–9.

    PubMed  Google Scholar 

  104. Glew RH, Moellering RC Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore). 1977;56:79–97.

    CAS  Google Scholar 

  105. Rodríguez CH, Nastro M, Weyland B, Losada M, Vay C, Famiglietti A. Bacteremias by Acinetobacter spp. and carbapenems resistance. Acta Bioquimica Clinica Latinoamericana. 2010;44:243–8.

    Google Scholar 

  106. Spanik S, Botek R, Pichna P, et al. Acinetobacter species bacteremia in neutropenic cancer patients: risk factors, symptomatology and outcome in 27 cases. Antiinfect Drugs Chemother. 1996;14:201–4.

    Google Scholar 

  107. Khurana P, Baliga S, Suchitra Shenoy M, Prasanna MP. A rising threat—risk factors and outcomes related to infections with Acinetobacter species. Asian J Pharm Clin Res. 2017;10:108–11.

    Google Scholar 

  108. Lewis RH, Sharpe JP, Swanson JM, Fabian TC, Croce MA, Magnotti LJ. Reinventing the wheel: impact of prolonged antibiotic exposure on multidrug-resistant ventilator-associated pneumonia in trauma patients. J Trauma Acute Care Surg. 2018;85:256–62.

    CAS  PubMed  Google Scholar 

  109. Mishra A, Mishra S, Jaganath G, Mittal RK, Gupta PK, Patra DP. Acinetobacter sepsis in newborns. Indian Pediatr. 1998;35:27–32.

    CAS  PubMed  Google Scholar 

  110. Iqbal Hossain M, Iqbal Kabir AK, Khan WA, Fuchs GJ. Acinetobacter bacteremia in patients with diarrhoeal disease. Epidemiol Infect. 1998;120:139–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Liu L, Dong L, Xu YB, Chen ZX, Fan JM. Clinical characteristics and antibiotic resistance in children with invasive Acinetobacter baumannii infection. Zhongguo Dang Dai Er Ke Za Zhi. 2013;15:379–82.

    CAS  PubMed  Google Scholar 

  112. Wilhelms SB, Walther SM, Sjöberg F, De Geer L. Causes of late mortality among ICU-treated patients with sepsis. Acta Anaesthesiol Scand. 2020;64:961–6.

    PubMed  Google Scholar 

  113. Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47:1140–5.

    PubMed  Google Scholar 

  114. Joung MK, Kwon KT, Kang CI, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect. 2010;61:212–8.

    PubMed  Google Scholar 

  115. Liao YT, Kuo SC, Lee YT, et al. Sheltering effect and indirect pathogenesis of carbapenem-resistant Acinetobacter baumannii in polymicrobial infection. Antimicrob Agents Chemother. 2014;58:3983–90.

    PubMed  PubMed Central  Google Scholar 

  116. Bhargava N, Sharma P, Capalash N. N-acyl homoserine lactone mediated interspecies interactions between A. baumannii and P. aeruginosa. Biofouling. 2012;28:813–22.

    CAS  PubMed  Google Scholar 

  117. Smith NM, Ang A, Tan F, et al. Interaction of Staphylococcus aureus and Acinetobacter baumannii during in vitro β-lactam exposure. Antimicrob Agents Chemother. 2021. https://doi.org/10.1128/AAC.02414-20.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012;64:282–90.

    PubMed  Google Scholar 

  119. Lee YT, Kuo SC, Yang SP, et al. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities? Clin Microbiol Infect. 2013;19:640–5.

    PubMed  Google Scholar 

  120. Fleiss JL. Statistical methods for rates and proportions. New York: Wiley; 1981.

    Google Scholar 

Download references

Funding

No external funding was received for this work.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Infectious Diseases, University Hospital of Heraklion, 71110, Heraklion, Crete, Greece

    Stamatis Karakonstantis

  2. Laboratory of Biostatistics, School of Medicine, University of Crete, Heraklion, Crete, Greece

    Evangelos I. Kritsotakis

Authors
  1. Stamatis Karakonstantis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangelos I. Kritsotakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stamatis Karakonstantis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 2740 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karakonstantis, S., Kritsotakis, E.I. Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex. Infection 49, 1149–1161 (2021). https://doi.org/10.1007/s15010-021-01663-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-021-01663-0

Keywords

Search

Navigation